Surgically treated ovarian endometriosis association with BRCA1 and BRCA2 mutations

被引:8
|
作者
Aviel-Ronen, Sarit [1 ,2 ]
Soriano, David [3 ,4 ]
Shmuel, Elyasaf [3 ]
Schonman, Ron [3 ]
Rosenblatt, Kinneret [1 ]
Zadok, Oranit [1 ]
Vituri, Aya [5 ]
Seidman, Daniel [3 ]
Barshack, Iris [1 ,4 ]
Cohen, Yoram [3 ,4 ]
机构
[1] Chaim Sheba Med Ctr, Dept Pathol, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Talpiot Med Leadership Program, IL-52621 Tel Hashomer, Israel
[3] Chaim Sheba Med Ctr, Dept Obstet & Gynecol, IL-52621 Tel Hashomer, Israel
[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[5] Tel Aviv Univ, Dept Stat & Operat Res, IL-69978 Tel Aviv, Israel
基金
以色列科学基金会;
关键词
Endometriosis; Ovarian cancer; BRCA1; BRCA2; MALDI-TOF-MS; BREAST-CANCER; GENE POLYMORPHISMS; CARRIER FREQUENCY; RISK; WOMEN; CARCINOMA; GSTM1; HETEROZYGOSITY; SUSCEPTIBILITY; TRANSFERASE;
D O I
10.1016/j.prp.2013.12.011
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Endometriosis is associated with an increased risk of ovarian cancer. Few studies have also shown increased risk of breast cancer. BRCA1/2 mutations are linked to an increased risk of breast and ovarian cancers but their relation to endometriosis is unknown. The objective of this study was to examine the mutation rate of BRCA1/2 among women with surgically treated ovarian endometriosis. We collected 126 specimens from Jewish Ashkenazi women with endometriotic (76) and control non-endometriotic (50) ovarian cysts, reviewed the pathological diagnoses and extracted DNA from all samples. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), samples were examined for the founder germline mutations of BRCA1/2, most common among Ashkenazi Jews. The rate of mutations in each group was calculated and compared. BRCA1/2 mutation rate was 1/76(1.3%) in the endometriotic cyst study group and 1/50(2%) in the control non-endometriotic cysts, showing no statistically significant difference between the groups (p = 0.84). BRCA1/2 mutation rate was similar to the previously reported rate among Jewish Ashkenazi women. BRCA1/2 mutation rates in patients with endometriotic ovarian cysts and with non-endometriotic ovarian cysts are similar. A larger cohort is required to completely exclude the possibility of an association between BRCA1/2 mutations and surgically treated endometriosis. (C) 2014 Elsevier GmbH. All rights reserved.
引用
收藏
页码:250 / 255
页数:6
相关论文
共 50 条
  • [22] Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
    Bolton, Kelly L.
    Chenevix-Trench, Georgia
    Goh, Cindy
    Sadetzki, Siegal
    Ramus, Susan J.
    Karlan, Beth Y.
    Lambrechts, Diether
    Despierre, Evelyn
    Barrowdale, Daniel
    McGuffog, Lesley
    Healey, Sue
    Easton, Douglas F.
    Sinilnikova, Olga
    Benitez, Javier
    Garcia, Maria J.
    Neuhausen, Susan
    Gail, Mitchell H.
    Hartge, Patricia
    Peock, Susan
    Frost, Debra
    Evans, Gareth
    Eeles, Rosalind
    Godwin, Andrew K.
    Daly, Mary B.
    Kwong, Ava
    Ma, Edmond S. K.
    Lazaro, Conxi
    Blanco, Ignacio
    Montagna, Marco
    D'Andrea, Emma
    Nicoletto, Maria Ornella
    Johnatty, Sharon E.
    Krueger, Susanne
    Jensen, Allan
    Hogdall, Estrid
    Goode, Ellen L.
    Fridley, Brooke L.
    Loud, Jennifer T.
    Greene, Mark H.
    Mai, Phuong L.
    Chetrit, Angela
    Lubin, Flora
    Hirsh-Yechezkel, Galit
    Glendon, Gord
    Andrulis, Irene L.
    Toland, Amanda E.
    Senter, Leigha
    Gore, Martin E.
    Gourley, Charlie
    Michie, Caroline O.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 382 - 390
  • [23] Association between BRCA1 and BRCA2 mutations and Survival in women with invasive epithelial Ovarian cancer
    Bremer, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (11) : 1057 - 1058
  • [24] Screening for Genetic Mutations in BRCA1 and BRCA2
    Narod, Steven
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2015, 22 (12): : 1365 - 1365
  • [25] Oophorectomy in women with BRCA1 or BRCA2 mutations
    Burki, Talha Khan
    LANCET ONCOLOGY, 2014, 15 (04): : E156 - E156
  • [26] Inactivation of BRCA1 and BRCA2 in ovarian cancer
    Hilton, JL
    Geisler, JP
    Rathe, JA
    Hattermann-Zogg, MA
    DeYoung, B
    Buller, RE
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (18): : 1396 - 1406
  • [27] The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
    Ramus, Susan J.
    Gayther, Simon A.
    MOLECULAR ONCOLOGY, 2009, 3 (02) : 138 - 150
  • [28] BRCA1 and BRCA2 Mutations and Breast Cancer
    Narod, Steven A.
    Salmena, Leonardo
    DISCOVERY MEDICINE, 2011, 12 (66) : 445 - 453
  • [29] Molecular Trajectory of BRCA1 and BRCA2 Mutations
    Hatano, Yuichiro
    Tamada, Maho
    Matsuo, Mikiko
    Hara, Akira
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [30] Founder mutations in BRCA1 and BRCA2 genes
    Ferla, R.
    Calo, V.
    Cascio, S.
    Rinaldi, G.
    Badalamenti, G.
    Carreca, I.
    Surmacz, E.
    Coliucci, G.
    Bazan, V.
    Russo, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 93 - 98